BIT 2.53% 8.1¢ biotron limited

Pixie the average CEO in the Australia is at the helm for eight...

  1. 1,081 Posts.
    lightbulb Created with Sketch. 375
    Pixie the average CEO in the Australia is at the helm for eight years; 90 per cent of CEOs stay less than 12 years. Of course, boards don’t always select the right CEO. Our favorite has only been here for 16 years and Chairman 18 years.

    http://www.companydirectors.com.au/...ons/september/kerin-how-long-should-ceos-stay

    Trial results within 27 sleeps, if the Eradication word rolls out in the presentation they should be well positioned to sign a commercial agreement well before the November options expire. Why may you ask?

    6th of Feb 2017 ASX Ann Humanised Mouse the fully analysed results will be presented in detail as soon as possible to an appropriate scientific conference and shared in confidence with potential commercial partners.


    18th Oct Annual Report
    The study in humanised mice and the current Phase 2 clinical trial are key to a commercial outcome for Biotron’s HIV-1 program. In parallel, the Company has been actively engaging with potential commercial partners through meetings held regularly throughout
    the year
    with several pharmaceutical companies active in the HIV-1 therapeutic area. Feedback has been positive and we anticipate entering commercial discussions with one or more of these parties on the back of positive data from the BIT225-009 trial.​


    20th of Nov 2017 ASX AGM Presentation
    Several pharmaceu'cal companies have ac've HIV-1 “Cure” Programs​
    Identified and qualified potential partners.
    Potential partners have defined their success criteria - we are aligned!
    Communicating trial data as soon as available.
    Follow meetings with potential partners continue.

    6th of April 2018 Update progress
    The new assay has been tested on samples from previous trials during this period of development and validation, and the results have demonstrated that the assay has the appropriate sensitivity and ability to quantify HIV-1 within reservoir cells. Work will now proceed on samples from the 009 trial.​


    Previous trial data can be shared with potential partners to demonstrate final outcome results. There should be no delay in a follow up TH to Ann commercial deal. Assay information has been available since April 2018, also Humunised Mouse data has apparently been shared with same potential partners since Feb 2017.

    If a potential partner was in the wings, do you think they would already be testing their Cart drugs with Bit225?

    Final word Pixel, if no deal by November 2018, I think there might be enough disgruntled SH's to vote off a couple of Board members and remove CEO with the new board members. KPI will be simple - Sell the lot......

    Of course all is IMHO.

    DYOR, good luck in 27 sleeps
 
watchlist Created with Sketch. Add BIT (ASX) to my watchlist
(20min delay)
Last
8.1¢
Change
0.002(2.53%)
Mkt cap ! $73.08M
Open High Low Value Volume
7.5¢ 8.1¢ 7.2¢ $87.51K 1.177M

Buyers (Bids)

No. Vol. Price($)
2 30000 7.7¢
 

Sellers (Offers)

Price($) Vol. No.
8.2¢ 312790 2
View Market Depth
Last trade - 15.39pm 29/03/2024 (20 minute delay) ?
Last
7.7¢
  Change
0.002 ( 0.00 %)
Open High Low Volume
7.5¢ 8.0¢ 7.3¢ 161454
Last updated 15.34pm 29/03/2024 ?
BIT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.